Radiotherapy & Oncology
Volume 89, Issue 2 , Pages 127-134 , November 2008

Cost-effectiveness of particle therapy: Current evidence and future needs

  • Madelon Pijls-Johannesma

      Affiliations

    • Maastricht Radiation Oncology (MAASTRO Clinic), University Medical Center, Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Madelon Pijls-Johannesma, Maastricht Radiation Oncology (MAASTRO Clinic), University Medical Center, Dr. Tanslaan 12, Postbus 5800, 6229 ET Maastricht, The Netherlands.
    • ,
  • Pascal Pommier

      Affiliations

    • Department of Radiation Oncology, Cancer Center Léon Bérard, Lyon, France
    • ,
  • Yolande Lievens

      Affiliations

    • Department of Radiation Oncology, University Hospital Gasthuisberg, Leuven, Belgium

Received 28 April 2008 ,Revised 15 July 2008 ,Accepted 16 July 2008.

References 

  1. Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836–849
  2. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–970
  3. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83:110–122
  4. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy – a systematic review of clinical effectiveness. Radiother Oncol. 2007;83:123–132
  5. Lievens Y. Valorisation of high technology radiotherapy in Europe. Cancer Radiother. 2006;10:361–369
  6. Glimelius B, Montelius A. Proton beam therapy – do we need the randomised trials and can we do them?. Radiother Oncol. 2007;83:105–109
  7. Lawrence T, Petrelli N, Li B, Galvin J. Think globally, act locally. J Clin Oncol. 2007;25:921–923
  8. Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue?. Radiother Oncol. 2008;86:142–147
  9. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  10. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008;86:148–153
  11. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet. 2002;360:711–715
  12. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006;
  13. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5 – working with Markov processes. Med Decis Making. 1997;17:152–159
  14. Drummond M, McGuuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2006;
  15. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (Royal College of Radiologists (Great Britain)). 2003;15:S37–S50
  16. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005;75:179–185
  17. Cohilis P, Jongen Y. Some factors influencing the cost of a hospital based proton therapy centre. Strahlenther Onkol. 1999;175:102–104
  18. Fleurette F, Charvet Protat S. Proton and neutron radiation in cancer treatment: clinical and economic outcomes. Bull Cancer Radiother. 1996;83:223s–227s
  19. Khoroshkov VS, Onosovsky KK, Klenov GI, Zink S. Moscow hospital-based proton therapy facility design. Am J Clin Oncol. 1994;17:109–114
  20. Knapp FF, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med. 1994;21:1151–1165
  21. Lievens Y, Van den Bogaert W. Proton beam therapy: too expensive to become true?. Radiother Oncol. 2005;75:131–133
  22. Maughan RL, Brambs B, Porter AT, Forman JD. The cost-effectiveness of mixed beam neutron-photon radiation therapy in the treatment of adenocarcinoma of the prostate. Strahlenther Onkol. 1999;175:104–107
  23. Pommier P, Zucca L, Naslund I, et al. Light ion facility projects in Europe: methodological aspects for the calculation of the treatment cost per protocol. Radiother Oncol. 2004;73:S183–185
  24. Battaglia G, Borgonovi E, Brugnoli M. Financial analysis of the activities of the hadron therapy centre. Part VI – costs and time schedule. In: The TERA Project and the Center for Oncology Hadrotherapy. INFN-LNF-Divisione Ricerca, 1994.
  25. Orecchia R, Zurlo A, Loasses A, et al. Particle beam therapy (hadrontherapy): basis for interest and clinical experience. Eur J Cancer. 1998;34:459–468
  26. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850–861
  27. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103:793–801
  28. Jakel O, Land B, Combs SE, Schulz-Ertner D, Debus J. On the cost-effectiveness of Carbon ion radiation therapy for skull base chordoma. Radiother Oncol. 2007;83:133–138
  29. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol. 2007;25:3603–3608
  30. Perrier L, Combs S, Auberger T, et al. A decision-making tool for a costly innovative technology: the case of Carbon ion radiotherapy. Journal d”Economie Médicale. 2007;25:367–380
  31. Pommier P, Gueye N, Buron C, et al. Medico-economic and Spatial Modelization for decision making in innovative therapies: application to light ions therapy projects in Europe. Radiother Oncol. 2006;81:S411
  32. Amaldi U. CNAO – the Italian centre for light-ion therapy. Radiother Oncol. 2004;73:S191–S201
  33. Bajard M, De Conto JM, Remillieux J. Status of the ETOILE” project for a French hadrontherapy centre. Radiother Oncol. 2004;73:S211–S215
  34. Griesmayer E, Auberger T. The status of MedAustron. Radiother Oncol. 2004;73:S202–S205
  35. Haberer T, Debus J, Eickhoff H, Jakel O, Schulz-Ertner D, Weber U. The heidelberg ion therapy center. Radiother Oncol. 2004;73:S186–S190
  36. Huybrechts M, Obyn C, Gailly J, Mambourg F, Vinck I, Ramaekers D, Hadrontherapy. HealthTechnology Assessment (HTA), Brussels: Federaal Keniscentrum voor de Gezondheidszorg (KCE) KCE Reports 67A, 2007.
  37. Lambin P, Fekkers H, Daniels E. Euregional ion therapy institute. Maastricht: Business plan; 2005;
  38. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol. 2008;86:217–223
  39. Lievens Y, Van den Bogaert W, Rijnders A, Kutcher G, Kesteloot K. Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?. Radiother Oncol. 2000;56:289–295
  40. Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol. 2005;75:349–354
  41. Tsujii H, Mizoe J, Kamada T, et al. Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res (Tokyo). 2007;48:A1–A13
  42. Tsujii H, Mizoe JE, Kamada T, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73:S41–S49

PII: S0167-8140(08)00380-0

doi: 10.1016/j.radonc.2008.07.015

Radiotherapy & Oncology
Volume 89, Issue 2 , Pages 127-134 , November 2008

Article Tools

* Image Usage & Resolution